News

Published on 4 May 2024 on Insider Monkey via Yahoo Finance

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript

Article preview image

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024

Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Read the rest of the article
NASDAQ.ABUS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’

We recently compiled a list of the Jim Cramer’s Lightning Round: 7 Stocks Under the Spotlight. In...

Insider Monkey · via Yahoo Finance 16 Jan 2025
Here’s Why Arbutus (ABUS) Surged in Q3

Tourlite Capital Management, an investment management firm, released its third quarter 2024 inves...

Insider Monkey · via Yahoo Finance 6 Dec 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus ...

Insider Monkey via Yahoo Finance 4 May 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since...

Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders are probably feeling a little disappoint...

Simply Wall St. via Yahoo Finance 3 Mar 2024
Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue...

Today is shaping up negative for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with t...

Simply Wall St. via Yahoo Finance 2 Mar 2024
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript February 29, 2024 Ar...

Insider Monkey via Yahoo Finance 1 Mar 2024
The past three years for Arbutus Biopharma (NASDAQ:ABUS) investors has not been profitable

Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders should be happy to see the share price u...

Simply Wall St. via Yahoo Finance 31 Jan 2024
Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors...

Key Insights Significant control over Arbutus Biopharma by individual investors implies that the ...

Simply Wall St. via Yahoo Finance 1 Jan 2024
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with t...

Simply Wall St. via Yahoo Finance 9 Nov 2023
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript November 7, 2023 Arb...

Insider Monkey via Yahoo Finance 9 Nov 2023

Copyright Statfolio @ 2025

Social Accounts